Skip to main content
Top
Published in: Diabetologia 10/2011

01-10-2011 | Article

C-reactive protein promotes diabetic kidney disease in a mouse model of type 1 diabetes

Authors: F. Liu, H. Y. Chen, X. R. Huang, A. C. K. Chung, L. Zhou, P. Fu, A. J. Szalai, H. Y. Lan

Published in: Diabetologia | Issue 10/2011

Login to get access

Abstract

Aims/hypothesis

Although C-reactive protein (CRP) has been implicated as a risk factor in diabetes, its pathogenic importance in diabetic kidney disease (DKD) remains unclear. The present study investigated the potential role of CRP in DKD.

Methods

Diabetes was induced by streptozotocin in human CRP transgenic and wild-type mice for assessment of kidney injury at 24 weeks by real-time PCR, immunohistochemistry and western blot analysis. In vitro, the pathogenic effect of CRP was investigated using human kidney tubular epithelial cells cultured with high glucose and/or CRP.

Results

We found that CRP transgenic mice developed much more severe diabetic kidney injury than wild-type mice, as indicated by a significant increase in urinary albumin excretion and kidney injury molecule-1 abundance, enhanced infiltration of macrophages and T cells, and upregulation of pro-inflammatory cytokines (IL-1β, TNFα) and extracellular matrix (collagen I, III and IV). Enhanced renal inflammation and fibrosis in CRP transgenic mice was associated with upregulation of CRP receptor, CD32a, and over-activation of the TGF-β/SMAD and nuclear factor κB signalling pathways. In vitro, CRP significantly upregulated pro-inflammatory cytokines (IL-1β, TNFα, monocyte chemoattractant protein-1 [MCP-1]) and pro-fibrotic growth factors (TGF-β1, connective tissue growth factor [CTGF]) via CD32a/64. CRP was induced by high glucose, which synergistically promoted high glucose-mediated renal inflammation and fibrosis.

Conclusions/interpretation

CRP is not only a biomarker, but also a mediator in DKD. Enhanced activation of TGF-β/SMAD and nuclear factor κB signalling pathways may be the mechanisms by which CRP promotes renal inflammation and fibrosis under diabetic conditions.
Appendix
Available only for authorised users
Literature
1.
go back to reference Navarro-Gonzalez JF, Mora-Fernandez C (2008) The role of inflammatory cytokines in diabetic nephropathy. J Am Soc Nephrol 19:433–442PubMedCrossRef Navarro-Gonzalez JF, Mora-Fernandez C (2008) The role of inflammatory cytokines in diabetic nephropathy. J Am Soc Nephrol 19:433–442PubMedCrossRef
2.
go back to reference Saraheimo M, Teppo AM, Forsblom C, Fagerudd J, Groop PH (2003) Diabetic nephropathy is associated with low-grade inflammation in type 1 diabetic patients. Diabetologia 46:1402–1407PubMedCrossRef Saraheimo M, Teppo AM, Forsblom C, Fagerudd J, Groop PH (2003) Diabetic nephropathy is associated with low-grade inflammation in type 1 diabetic patients. Diabetologia 46:1402–1407PubMedCrossRef
3.
go back to reference Tuttle KR (2005) Linking metabolism and immunology: diabetic nephropathy is an inflammatory disease. J Am Soc Nephrol 16:1537–1538PubMedCrossRef Tuttle KR (2005) Linking metabolism and immunology: diabetic nephropathy is an inflammatory disease. J Am Soc Nephrol 16:1537–1538PubMedCrossRef
4.
go back to reference Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM (2001) C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 286:327–334PubMedCrossRef Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM (2001) C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 286:327–334PubMedCrossRef
5.
go back to reference Schalkwijk CG, Poland DC, van Dijk W et al (1999) Plasma concentration of C-reactive protein is increased in type I diabetic patients without clinical macroangiopathy and correlates with markers of endothelial dysfunction: evidence for chronic inflammation. Diabetologia 42:351–357PubMedCrossRef Schalkwijk CG, Poland DC, van Dijk W et al (1999) Plasma concentration of C-reactive protein is increased in type I diabetic patients without clinical macroangiopathy and correlates with markers of endothelial dysfunction: evidence for chronic inflammation. Diabetologia 42:351–357PubMedCrossRef
6.
go back to reference Pfutzner A, Forst T (2006) High-sensitivity C-reactive protein as cardiovascular risk marker in patients with diabetes mellitus. Diabetes Technol Ther 8:28–36PubMedCrossRef Pfutzner A, Forst T (2006) High-sensitivity C-reactive protein as cardiovascular risk marker in patients with diabetes mellitus. Diabetes Technol Ther 8:28–36PubMedCrossRef
7.
go back to reference Ridker PM (2009) C-reactive protein: eighty years from discovery to emergence as a major risk marker for cardiovascular disease. Clin Chem 55:209–215PubMedCrossRef Ridker PM (2009) C-reactive protein: eighty years from discovery to emergence as a major risk marker for cardiovascular disease. Clin Chem 55:209–215PubMedCrossRef
8.
go back to reference Abrahamian H, Endler G, Exner M et al (2007) Association of low-grade inflammation with nephropathy in type 2 diabetic patients: role of elevated CRP-levels and 2 different gene-polymorphisms of proinflammatory cytokines. Exp Clin Endocrinol Diabetes 115:38–41PubMedCrossRef Abrahamian H, Endler G, Exner M et al (2007) Association of low-grade inflammation with nephropathy in type 2 diabetic patients: role of elevated CRP-levels and 2 different gene-polymorphisms of proinflammatory cytokines. Exp Clin Endocrinol Diabetes 115:38–41PubMedCrossRef
9.
go back to reference Stehouwer CD, Gall MA, Twisk JW, Knudsen E, Emeis JJ, Parving HH (2002) Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: progressive, interrelated, and independently associated with risk of death. Diabetes 51:1157–1165PubMedCrossRef Stehouwer CD, Gall MA, Twisk JW, Knudsen E, Emeis JJ, Parving HH (2002) Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: progressive, interrelated, and independently associated with risk of death. Diabetes 51:1157–1165PubMedCrossRef
10.
go back to reference Sabanayagam C, Lee J, Shankar A, Lim SC, Wong TY, Tai ES (2009) C-reactive protein and microalbuminuria in a multi-ethnic Asian population. Nephrol Dial Transplant 25:1167–1172PubMedCrossRef Sabanayagam C, Lee J, Shankar A, Lim SC, Wong TY, Tai ES (2009) C-reactive protein and microalbuminuria in a multi-ethnic Asian population. Nephrol Dial Transplant 25:1167–1172PubMedCrossRef
11.
go back to reference Goldberg RB (2009) Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced coagulation in development of diabetes and its complications. J Clin Endocrinol Metab 94:3171–3182PubMedCrossRef Goldberg RB (2009) Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced coagulation in development of diabetes and its complications. J Clin Endocrinol Metab 94:3171–3182PubMedCrossRef
12.
go back to reference Mugabo Y, Li L, Renier G (2010) The connection between C-reactive protein (CRP) and diabetic vasculopathy. Focus on preclinical findings. Current Diabetes Reviews 6:27–34PubMedCrossRef Mugabo Y, Li L, Renier G (2010) The connection between C-reactive protein (CRP) and diabetic vasculopathy. Focus on preclinical findings. Current Diabetes Reviews 6:27–34PubMedCrossRef
13.
go back to reference Pepys MB, Hirschfield GM, Tennent GA et al (2006) Targeting C-reactive protein for the treatment of cardiovascular disease. Nature 440:1217–1221PubMedCrossRef Pepys MB, Hirschfield GM, Tennent GA et al (2006) Targeting C-reactive protein for the treatment of cardiovascular disease. Nature 440:1217–1221PubMedCrossRef
14.
go back to reference Ridker PM (2009) The JUPITER trial: results, controversies, and implications for prevention. Circulation 2:279–285PubMed Ridker PM (2009) The JUPITER trial: results, controversies, and implications for prevention. Circulation 2:279–285PubMed
15.
go back to reference Ridker PM, Danielson E, Fonseca FA et al (2008) Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359:2195–2207PubMedCrossRef Ridker PM, Danielson E, Fonseca FA et al (2008) Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359:2195–2207PubMedCrossRef
16.
go back to reference Danenberg HD, Szalai AJ, Swaminathan RV et al (2003) Increased thrombosis after arterial injury in human C-reactive protein-transgenic mice. Circulation 108:512–515PubMedCrossRef Danenberg HD, Szalai AJ, Swaminathan RV et al (2003) Increased thrombosis after arterial injury in human C-reactive protein-transgenic mice. Circulation 108:512–515PubMedCrossRef
17.
go back to reference Paul A, Ko KW, Li L et al (2004) C-reactive protein accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. Circulation 109:647–655PubMedCrossRef Paul A, Ko KW, Li L et al (2004) C-reactive protein accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. Circulation 109:647–655PubMedCrossRef
18.
go back to reference Zhang R, Zhang YY, Huang XR et al (2010) C-reactive protein promotes cardiac fibrosis and inflammation in angiotensin II-induced hypertensive cardiac disease. Hypertension 55:953–960PubMedCrossRef Zhang R, Zhang YY, Huang XR et al (2010) C-reactive protein promotes cardiac fibrosis and inflammation in angiotensin II-induced hypertensive cardiac disease. Hypertension 55:953–960PubMedCrossRef
19.
go back to reference Brosius FC 3rd, Alpers CE, Bottinger EP et al (2009) Mouse models of diabetic nephropathy. J Am Soc Nephrol 20:2503–2512PubMedCrossRef Brosius FC 3rd, Alpers CE, Bottinger EP et al (2009) Mouse models of diabetic nephropathy. J Am Soc Nephrol 20:2503–2512PubMedCrossRef
20.
go back to reference Szalai AJ, McCrory MA (2002) Varied biologic functions of C-reactive protein: lessons learned from transgenic mice. Immunologic research 26:279–287PubMedCrossRef Szalai AJ, McCrory MA (2002) Varied biologic functions of C-reactive protein: lessons learned from transgenic mice. Immunologic research 26:279–287PubMedCrossRef
21.
go back to reference Lan HY, Mu W, Nikolic-Paterson DJ, Atkins RC (1995) A novel, simple, reliable, and sensitive method for multiple immunoenzyme staining: use of microwave oven heating to block antibody crossreactivity and retrieve antigens. J Histochem Cytochem 43:97–102PubMedCrossRef Lan HY, Mu W, Nikolic-Paterson DJ, Atkins RC (1995) A novel, simple, reliable, and sensitive method for multiple immunoenzyme staining: use of microwave oven heating to block antibody crossreactivity and retrieve antigens. J Histochem Cytochem 43:97–102PubMedCrossRef
22.
go back to reference Huang XR, Chung AC, Zhou L, Wang XJ, Lan HY (2008) Latent TGF-beta1 protects against crescentic glomerulonephritis. J Am Soc Nephrol 19:233–242PubMedCrossRef Huang XR, Chung AC, Zhou L, Wang XJ, Lan HY (2008) Latent TGF-beta1 protects against crescentic glomerulonephritis. J Am Soc Nephrol 19:233–242PubMedCrossRef
23.
go back to reference Chung AC, Huang XR, Zhou L, Heuchel R, Lai KN, Lan HY (2009) Disruption of the Smad7 gene promotes renal fibrosis and inflammation in unilateral ureteral obstruction (UUO) in mice. Nephrol Dial Transplant 24:1443–1454PubMedCrossRef Chung AC, Huang XR, Zhou L, Heuchel R, Lai KN, Lan HY (2009) Disruption of the Smad7 gene promotes renal fibrosis and inflammation in unilateral ureteral obstruction (UUO) in mice. Nephrol Dial Transplant 24:1443–1454PubMedCrossRef
24.
go back to reference Hong SW, Isono M, Chen S, Iglesias-De La Cruz MC, Han DC, Ziyadeh FN (2001) Increased glomerular and tubular expression of transforming growth factor-beta1, its type II receptor, and activation of the Smad signaling pathway in the db/db mouse. Am J Pathol 158:1653–1663PubMedCrossRef Hong SW, Isono M, Chen S, Iglesias-De La Cruz MC, Han DC, Ziyadeh FN (2001) Increased glomerular and tubular expression of transforming growth factor-beta1, its type II receptor, and activation of the Smad signaling pathway in the db/db mouse. Am J Pathol 158:1653–1663PubMedCrossRef
25.
go back to reference Li JH, Huang XR, Zhu HJ et al (2004) Advanced glycation end products activate Smad signaling via TGF-beta-dependent and independent mechanisms: implications for diabetic renal and vascular disease. Faseb J 18:176–178PubMedCrossRef Li JH, Huang XR, Zhu HJ et al (2004) Advanced glycation end products activate Smad signaling via TGF-beta-dependent and independent mechanisms: implications for diabetic renal and vascular disease. Faseb J 18:176–178PubMedCrossRef
26.
go back to reference Mezzano S, Aros C, Droguett A et al (2004) NF-kappaB activation and overexpression of regulated genes in human diabetic nephropathy. Nephrol Dial Transplant 19:2505–2512PubMedCrossRef Mezzano S, Aros C, Droguett A et al (2004) NF-kappaB activation and overexpression of regulated genes in human diabetic nephropathy. Nephrol Dial Transplant 19:2505–2512PubMedCrossRef
27.
go back to reference Fujimoto M, Maezawa Y, Yokote K et al (2003) Mice lacking Smad3 are protected against streptozotocin-induced diabetic glomerulopathy. Biochem Biophys Res Commun 305:1002–1007PubMedCrossRef Fujimoto M, Maezawa Y, Yokote K et al (2003) Mice lacking Smad3 are protected against streptozotocin-induced diabetic glomerulopathy. Biochem Biophys Res Commun 305:1002–1007PubMedCrossRef
28.
go back to reference Wang A, Ziyadeh FN, Lee EY et al (2007) Interference with TGF-beta signaling by Smad3-knockout in mice limits diabetic glomerulosclerosis without affecting albuminuria. Am J Physiol 293:F1657–F1665CrossRef Wang A, Ziyadeh FN, Lee EY et al (2007) Interference with TGF-beta signaling by Smad3-knockout in mice limits diabetic glomerulosclerosis without affecting albuminuria. Am J Physiol 293:F1657–F1665CrossRef
29.
go back to reference Ballou SP, Lozanski G (1992) Induction of inflammatory cytokine release from cultured human monocytes by C-reactive protein. Cytokine 4:361–368PubMedCrossRef Ballou SP, Lozanski G (1992) Induction of inflammatory cytokine release from cultured human monocytes by C-reactive protein. Cytokine 4:361–368PubMedCrossRef
30.
go back to reference Hanriot D, Bello G, Ropars A et al (2008) C-reactive protein induces pro- and anti-inflammatory effects, including activation of the liver X receptor alpha, on human monocytes. Thromb Haemost 99:558–569PubMed Hanriot D, Bello G, Ropars A et al (2008) C-reactive protein induces pro- and anti-inflammatory effects, including activation of the liver X receptor alpha, on human monocytes. Thromb Haemost 99:558–569PubMed
31.
go back to reference Liang YJ, Shyu KG, Wang BW, Lai LP (2006) C-reactive protein activates the nuclear factor-kappaB pathway and induces vascular cell adhesion molecule-1 expression through CD32 in human umbilical vein endothelial cells and aortic endothelial cells. J Mol Cell Cardiol 40:412–420PubMedCrossRef Liang YJ, Shyu KG, Wang BW, Lai LP (2006) C-reactive protein activates the nuclear factor-kappaB pathway and induces vascular cell adhesion molecule-1 expression through CD32 in human umbilical vein endothelial cells and aortic endothelial cells. J Mol Cell Cardiol 40:412–420PubMedCrossRef
32.
go back to reference Mold C, Du Clos TW (2006) C-reactive protein increases cytokine responses to Streptococcus pneumoniae through interactions with Fc gamma receptors. J Immunol 176:7598–7604PubMed Mold C, Du Clos TW (2006) C-reactive protein increases cytokine responses to Streptococcus pneumoniae through interactions with Fc gamma receptors. J Immunol 176:7598–7604PubMed
33.
go back to reference Guan H, Wang P, Hui R et al (2009) Adeno-associated virus-mediated human C-reactive protein gene delivery causes endothelial dysfunction and hypertension in rats. Clin Chem 55:274–284PubMedCrossRef Guan H, Wang P, Hui R et al (2009) Adeno-associated virus-mediated human C-reactive protein gene delivery causes endothelial dysfunction and hypertension in rats. Clin Chem 55:274–284PubMedCrossRef
34.
go back to reference Pasceri V, Chang J, Willerson J et al (2001) Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation 103:2531–2534PubMed Pasceri V, Chang J, Willerson J et al (2001) Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation 103:2531–2534PubMed
35.
go back to reference Li JH, Huang XR, Zhu HJ, Johnson R, Lan HY (2003) Role of TGF-beta signaling in extracellular matrix production under high glucose conditions. Kidney Int 63:2010–2019PubMedCrossRef Li JH, Huang XR, Zhu HJ, Johnson R, Lan HY (2003) Role of TGF-beta signaling in extracellular matrix production under high glucose conditions. Kidney Int 63:2010–2019PubMedCrossRef
36.
go back to reference Sharma K, Jin Y, Guo J, Ziyadeh FN (1996) Neutralization of TGF-beta by anti-TGF-beta antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice. Diabetes 45:522–530PubMedCrossRef Sharma K, Jin Y, Guo J, Ziyadeh FN (1996) Neutralization of TGF-beta by anti-TGF-beta antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice. Diabetes 45:522–530PubMedCrossRef
37.
go back to reference Ziyadeh FN, Hoffman BB, Han DC et al (2000) Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. Proc Natl Acad Sci USA 97:8015–8020PubMedCrossRef Ziyadeh FN, Hoffman BB, Han DC et al (2000) Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. Proc Natl Acad Sci USA 97:8015–8020PubMedCrossRef
38.
go back to reference Lu B, Yang Y, Yang Z et al (2010) Insulin resistance in Chinese patients with type 2 diabetes is associated with C-reactive protein independent of abdominal obesity. Cardiovasc Diabetol 9:92PubMedCrossRef Lu B, Yang Y, Yang Z et al (2010) Insulin resistance in Chinese patients with type 2 diabetes is associated with C-reactive protein independent of abdominal obesity. Cardiovasc Diabetol 9:92PubMedCrossRef
39.
go back to reference Kaneko H, Anzai T, Nagai T et al. (2011) Human C-reactive protein exacerbates metabolic disorders in association with adipose tissue remodelling. Cardiovasc Res. doi:10.1093/cvr/cvr088 Kaneko H, Anzai T, Nagai T et al. (2011) Human C-reactive protein exacerbates metabolic disorders in association with adipose tissue remodelling. Cardiovasc Res. doi:10.​1093/​cvr/​cvr088
40.
go back to reference Tanigaki K, Mineo C, Yuhanna IS et al (2009) C-reactive protein inhibits insulin activation of endothelial nitric oxide synthase via the immunoreceptor tyrosine-based inhibition motif of FcgammaRIIB and SHIP-1. Circ Res 104:1275–1282PubMedCrossRef Tanigaki K, Mineo C, Yuhanna IS et al (2009) C-reactive protein inhibits insulin activation of endothelial nitric oxide synthase via the immunoreceptor tyrosine-based inhibition motif of FcgammaRIIB and SHIP-1. Circ Res 104:1275–1282PubMedCrossRef
41.
go back to reference Takahashi T, Anzai T, Kaneko H et al (2010) Increased C-reactive protein expression exacerbates left ventricular dysfunction and remodeling after myocardial infarction. Am J Physiol Heart Circ Physiol 299:H1795–H1804PubMedCrossRef Takahashi T, Anzai T, Kaneko H et al (2010) Increased C-reactive protein expression exacerbates left ventricular dysfunction and remodeling after myocardial infarction. Am J Physiol Heart Circ Physiol 299:H1795–H1804PubMedCrossRef
42.
go back to reference Vongpatanasin W, Thomas GD, Schwartz R et al (2007) C-reactive protein causes downregulation of vascular angiotensin subtype 2 receptors and systolic hypertension in mice. Circulation 115:1020–1028PubMedCrossRef Vongpatanasin W, Thomas GD, Schwartz R et al (2007) C-reactive protein causes downregulation of vascular angiotensin subtype 2 receptors and systolic hypertension in mice. Circulation 115:1020–1028PubMedCrossRef
43.
go back to reference Han K, Hong KH, Park JH et al (2004) C-Reactive protein promotes monocyte chemoattractant protein-1-mediated chemotaxis through upregulating CC chemokine receptor 2 expression in human monocytes. Circulation 109:2566–2571PubMedCrossRef Han K, Hong KH, Park JH et al (2004) C-Reactive protein promotes monocyte chemoattractant protein-1-mediated chemotaxis through upregulating CC chemokine receptor 2 expression in human monocytes. Circulation 109:2566–2571PubMedCrossRef
Metadata
Title
C-reactive protein promotes diabetic kidney disease in a mouse model of type 1 diabetes
Authors
F. Liu
H. Y. Chen
X. R. Huang
A. C. K. Chung
L. Zhou
P. Fu
A. J. Szalai
H. Y. Lan
Publication date
01-10-2011
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 10/2011
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-011-2237-y

Other articles of this Issue 10/2011

Diabetologia 10/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.